CION Ameerpet
A stem cell transplant — often called a bone marrow transplant (BMT) — offers high-dose treatment for relapsed or refractory lymphoma. This guide explains autologous vs allogeneic transplant, the steps, recovery and risks, and how CION coordinates your care with accredited transplant centres.
A stem cell transplant for lymphoma — also called a bone marrow transplant (BMT) — is a way to give very high-dose treatment while protecting the body's blood-forming system. High-dose chemotherapy (sometimes with radiation) is powerful enough to destroy lymphoma cells that lower-dose treatment left behind, but it also wipes out the bone marrow, where blood cells are made. To rescue the marrow, healthy blood-forming stem cells are infused afterwards. They travel to the bone marrow and rebuild your blood and immune system over the following weeks.
The term "bmt lymphoma" is often used interchangeably with stem cell transplant. In modern practice the stem cells are usually collected from the bloodstream rather than the bone marrow itself, but the goal is the same: to allow intensive therapy and then restore healthy blood production. A transplant is intensive treatment, so it is used selectively — most commonly for relapsed or refractory lymphoma rather than as first-line care.
This overview explains the two main types of transplant, when a transplant is considered, the steps involved, recovery and risks. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
For selected patients with chemo-sensitive relapsed aggressive lymphoma, high-dose therapy followed by an autologous stem cell transplant has long been a recognised standard of care in international guidelines. Both NCCN (US) and ESMO (Europe) list autologous transplant as a consolidation option in this setting, provided the lymphoma still responds to salvage chemotherapy — which is why getting the disease back under control before transplant matters so much. (Source: NCCN and ESMO clinical practice guidelines for lymphoma.)
There are two broad types of stem cell transplant in lymphoma. Which one is right depends on the subtype, how the lymphoma has responded to treatment, your age and fitness — a decision made jointly by your oncologist and the transplant team.
In an autologous stem cell transplant, your own healthy stem cells are collected and frozen before high-dose chemotherapy, then returned to you afterwards. It is the more common approach in lymphoma and is often used for chemo-sensitive relapsed aggressive disease. Because the cells are your own, there is no graft-versus-host disease and no need for a donor.
In an allogeneic (donor) transplant, stem cells come from a matched donor — often a sibling or a matched unrelated donor. Donor cells add an immune effect against the lymphoma (a graft-versus-lymphoma effect) but carry a higher risk of complications, including graft-versus-host disease. It is reserved for selected situations, such as relapse after an earlier autologous transplant.
A stem cell transplant is delivered at a specialised inpatient facility. CION coordinates that step through accredited partner transplant centres, while managing the rest of your journey directly and close to home.
Considering your options? Book a free consultation or explore the best lymphoma hospital in Hyderabad and our lymphoma specialists.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether your lymphoma has relapsed, you want to understand if a transplant is right for you, or you need a second opinion before a decision — CION's team is here to guide you.
A stem cell transplant is not part of first-line treatment for most people with lymphoma. Standard first-line therapy — usually chemotherapy with or without an anti-CD20 monoclonal antibody, sometimes with radiation — cures or controls the majority of cases. A transplant is considered in more specific situations:
Newer therapies have also reshaped the sequence. For some patients, CAR T-cell therapy, immunotherapy and monoclonal antibodies, or bispecific antibodies may be considered before or instead of transplant. The right pathway is chosen by the tumour board, following NCCN and ESMO guidance — the full list of options is on our Lymphoma Treatment in Hyderabad page.
A transplant unfolds over several weeks. Understanding the phases helps you and your family prepare. CION manages the outpatient work-up and salvage treatment; the inpatient transplant is delivered at an accredited partner facility.
First, tests confirm the lymphoma is responding to salvage treatment and that your heart, lungs, kidneys and liver can tolerate high-dose therapy. A relapsed or refractory lymphoma generally needs to be chemo-sensitive before a transplant is planned.
For an autologous transplant, your own stem cells are mobilised into the bloodstream and collected, then frozen. For an allogeneic transplant, a matched donor is identified and their cells are collected. This is often done through a central line and is generally well tolerated.
High-dose conditioning chemotherapy — sometimes with radiation — is given to destroy remaining lymphoma cells and, for donor transplants, to make room for the new immune system. This is the most intensive part and is done as an inpatient.
The stem cells are infused much like a blood transfusion. Over about two to four weeks they settle into the bone marrow and begin making new blood cells — a process called engraftment. You stay in a protected environment during this time because blood counts, and therefore infection risk, are at their lowest.
A stem cell transplant is intensive, and being prepared for recovery makes a real difference. Recovery happens in stages, and the timeline depends on the type of transplant, your age and overall health.
While the new marrow engrafts, blood counts are low, so infection, bleeding and anaemia are the main early risks. Mucous-membrane soreness, nausea and fatigue are common from the conditioning. This phase is managed in a specialised transplant unit with close monitoring. Managing symptoms is a shared skill — our guide to managing chemotherapy side effects and what to expect during an infusion may help.
The immune system rebuilds slowly. Most people feel gradually stronger over three to six months, though full recovery of energy and immunity can take a year or longer — particularly after an allogeneic transplant. Regular blood tests, re-vaccination and surveillance for late effects are part of follow-up, which CION coordinates locally.
After a donor transplant, graft-versus-host disease — where donor immune cells attack the recipient's own tissues — is an added risk that needs immune-suppressing medicine and careful monitoring. This is one reason allogeneic transplants are used more selectively than autologous ones.
Outcomes depend heavily on the lymphoma subtype and how it responded before transplant. As context, published series report that many people with Hodgkin lymphoma achieve long-term survival in the region of 80–90%, while diffuse large B-cell (DLBCL) outcomes are often around 60–70% — figures that come from broad datasets, not transplant alone, and that vary considerably by individual (source: published clinical series cited in NCCN and ESMO guidelines). Your team can give you a realistic picture for your own situation.
A transplant decision is significant, and a second opinion is especially valuable when:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726. You can also explore care for related conditions on our leukemia and blood cancer hubs.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if your lymphoma has relapsed and you're weighing transplant against newer options.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A stem cell transplant — often called a bone marrow transplant in lymphoma — is a way to give very high-dose treatment while rescuing the blood-forming system. High-dose chemotherapy destroys lymphoma cells but also wipes out the bone marrow, so healthy blood-forming stem cells are then infused to rebuild it. The stem cells can come from you (an autologous transplant) or from a matched donor (an allogeneic transplant). Transplant is not first-line treatment for most people; it is usually considered for relapsed or refractory lymphoma after standard therapy. At CION, transplant is coordinated through accredited partner transplant centres, with your work-up, referral and follow-up managed by our team.
The difference is where the stem cells come from. In an autologous transplant, your own stem cells are collected and frozen before high-dose chemotherapy, then given back afterwards — this is the more common approach in lymphoma. In an allogeneic (donor) transplant, stem cells come from a matched donor, often a sibling or an unrelated matched donor. An allogeneic transplant adds an immune effect against the lymphoma (a graft-versus-lymphoma effect) but carries a higher risk of complications such as graft-versus-host disease. The choice depends on your lymphoma subtype, how it has responded to treatment, your age and fitness, and is decided jointly by the transplant team and your oncologist per NCCN and ESMO guidance.
A BMT for lymphoma is not usually part of first-line treatment. It is most often considered when aggressive lymphoma comes back after initial therapy (relapse) or does not respond fully (refractory disease), and when the disease still responds to salvage chemotherapy. For some chemo-sensitive relapsed aggressive lymphomas, an autologous transplant is a recognised standard option. Allogeneic transplant is reserved for selected situations, such as relapse after an earlier autologous transplant or certain high-risk subtypes. Eligibility depends on the lymphoma subtype, response to salvage treatment, age, organ function and overall fitness. Newer options such as CAR T-cell therapy have also changed the sequence for some patients. The decision is always made by a tumour board — see our Lymphoma Treatment in Hyderabad page.
There are broadly four phases. First, work-up: tests confirm the lymphoma is responding to salvage treatment and that your heart, lungs, kidneys and liver can tolerate the procedure. Second, stem cell collection: for an autologous transplant your own stem cells are mobilised into the blood and collected; for an allogeneic transplant a matched donor is found and their cells are collected. Third, conditioning: high-dose chemotherapy (sometimes with radiation) is given to destroy remaining lymphoma. Fourth, the transplant itself — the stem cells are infused like a blood transfusion, after which they travel to the bone marrow and start making new blood cells (engraftment) over about two to four weeks. A hospital stay and close monitoring follow. These inpatient steps are delivered at an accredited partner transplant facility that CION coordinates with.
Recovery happens in stages. The early phase — while the new marrow engrafts and blood counts recover — usually means two to four weeks in a specialised transplant unit, with protection against infection. Over the next few months the immune system slowly rebuilds; most people feel gradually stronger over three to six months, though full recovery of energy and immunity can take a year or longer, particularly after an allogeneic transplant. During this time you will have regular blood tests, may need re-vaccination, and are watched for late effects and, after donor transplants, for graft-versus-host disease. CION coordinates this follow-up locally so you are supported close to home. Recovery time varies with the type of transplant, your age and overall health.
A transplant is intensive treatment and carries real risks that are discussed carefully beforehand. In the early phase, low blood counts raise the risk of infection, bleeding and anaemia, and mucous-membrane soreness (mucositis), nausea and fatigue are common from the high-dose conditioning. After an allogeneic (donor) transplant, graft-versus-host disease — where donor immune cells attack the recipient's tissues — is an added risk that needs immune-suppressing medicine. Longer term, effects on fertility, hormones and a small risk of second cancers are discussed. Modern supportive care has made transplant safer, but it is only recommended when the likely benefit outweighs these risks. Your transplant team will explain the specific risks for your situation before you consent.
CION coordinates stem cell and bone marrow transplants through accredited partner transplant centres rather than performing the inpatient transplant in-house. Our role is to manage everything around it: confirming the diagnosis and subtype, delivering the salvage chemotherapy and immunotherapy that gets the lymphoma into a transplant-ready state, running the pre-transplant work-up, presenting your case to the tumour board, referring you to the right transplant facility, and then providing your follow-up and survivorship care locally. We deliver chemotherapy, antibody and targeted therapy, radiation and monitoring directly. For a full overview of options, see our Lymphoma Treatment in Hyderabad page or book a free consultation.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.